ZUCARA THERAPEUTICS
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.
ZUCARA THERAPEUTICS
Industry:
Biotechnology Diabetes Pharmaceutical
Founded:
2015-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.zucara.ca
Total Employee:
11+
Status:
Active
Total Funding:
28.81 M USD
Technology used in webpage:
CrUX Top 50m CrUX Dataset
Similar Organizations
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
JDRF (The Juvenile Diabetes Research Foundation)
JDRF (The Juvenile Diabetes Research Foundation) investment in Grant - Zucara Therapeutics
Mitacs
Mitacs investment in Grant - Zucara Therapeutics
Canadian Glycomics Network
Canadian Glycomics Network investment in Grant - Zucara Therapeutics
Mitacs
Mitacs investment in Grant - Zucara Therapeutics
National Research Council of Canada Industrial Research Assistance Program
National Research Council of Canada Industrial Research Assistance Program investment in Grant - Zucara Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series A - Zucara Therapeutics
Canadian Glycomics Network
Canadian Glycomics Network investment in Grant - Zucara Therapeutics
The Leona M. and Harry B. Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust investment in Grant - Zucara Therapeutics
JDRF (The Juvenile Diabetes Research Foundation)
JDRF (The Juvenile Diabetes Research Foundation) investment in Grant - Zucara Therapeutics
Centre for Drug Research and Development
Centre for Drug Research and Development investment in Grant - Zucara Therapeutics
Official Site Inspections
http://www.zucara.ca
- Host name: hosting.webnames.ca
- IP address: 209.15.37.21
- Location: Vancouver Canada
- Latitude: 49.245
- Longitude: -123.1337
- Timezone: America/Vancouver
- Postal: V6H
More informations about "Zucara Therapeutics"
About Us | Zucara Therapeutics
Zucara Therapeutics was created in 2014 as a spin-out company by TIAP (Toronto Innovation Acceleration Partners) and adMare BioInnovations. ... These activities were supported by over …See details»
JDRF Funds Zucara Therapeutics’ Approach to Preventing …
Sep 21, 2017 NEW YORK, USA and TORONTO, Canada, September 21, 2017 — As Global Biotech Week begins in more than 20 countries, JDRF, the leading organization funding type 1 …See details»
TIAP FEATURES: Zucara Therapeutics – Building on Canada’s Rich …
Zucara attracted over US$9M in subsequent funding from organizations such as JDRF International, The Helmsley Charitable Trust, NRC-IRAP, MITACS, and GlycoNet. This …See details»
Zucara Therapeutics | Ontario Bioscience Innovation Organization …
Search job openings across the Ontario Bioscience Innovation Organization network. ... Search jobs. Explore companies Talent network. My job alerts. Zucara Therapeutics. zucara.ca. …See details»
GlycoNet-supported Zucara Therapeutics Inc. named Emerging …
6 days ago Congratulations to the Zucara Therapeutics team on receiving the 2025 Emerging Company of the Year award from Life Sciences Ontario. ... The company has raised over …See details»
Zucara Therapeutics Announces Strategic Investment
Toronto, Canada, November 12, 2024 – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent …See details»
Zucara - University of Toronto Entrepreneurship
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. ... The University of Toronto has been recognized as best-in-class by one of the leading …See details»
Zucara Therapeutics Announces Additional Funding from JDRF to …
Jun 15, 2023 TORONTO, ON — Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent …See details»
Helping people with diabetes sleep safely and soundly - zucara.ca
Nov 14, 2018 Zucara has raised US$7M in funding to date from various organizations including its founding institutions: CDRD and MaRS Innovation; leading diabetes organizations: The …See details»
Zucara Therapeutics Announces Additional Funding
Toronto, Canada, June 15, 2023 – Zucara Therapeutics Inc., (“Zucara” or the “Company”), a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent …See details»
Zucara Therapeutics Announces Strategic Investment from
Nov 12, 2024 Zucara Therapeutics, a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with …See details»
Zucara Therapeutics Secures US$3.9M from the Helmsley …
“It is a unique opportunity for us to work with the Helmsley Charitable Trust, an organization that is deeply involved in bringing Type 1 diabetes (T1D) technologies and therapies to people with …See details»
Zucara Therapeutics - Crunchbase Company Profile & Funding
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. ... www.zucara.ca ; 40,896; Highlights. obfuscated. …See details»
Zucara 2025 Company Profile: Valuation, Funding & Investors
Zucara General Information Description. Developer of a novel drug therapy designed to prevent hypoglycemia in people with diabetes. The company's drug therapy is delivered as a …See details»
Susan Peers Joins Zucara’s Leadership Team
Mar 13, 2019 Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin …See details»
Zucara Therapeutics Inc. - Life Sciences British Columbia
Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit …See details»
Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial
Sep 25, 2023 TORONTO, ON — Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes life sciences company developing the first once-daily therapeutic to prevent …See details»
Zucara Therapeutics Secures Additional Funding from GlycoNet …
May 2, 2022 The project was granted nearly $150,000, which Zucara will more than double match to fund its preclinical efficacy study of ZT-01 for T2D. Mitacs has awarded Zucara and …See details»
Good for mining but bad for democracy? Why Indigenous groups …
1 day ago Ecuador’s largest Indigenous organization is vowing to fight a proposed free trade agreement with Canada. Critics say the deal favours mining corporations and could encourage …See details»
Zucara Therapeutics Expands ZT-01 Development Program to …
On September 29, 2020, Zucara dosed the first subject in its ongoing Phase 1 clinical trial of ZT-01 for the prevention of insulin-induced hypoglycemia in patients with T1D. About Mitacs. …See details»